Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Active not recruiting 2

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Pancreatic Neoplasms 205Carcinoma, Non-Small-Cell Lung 130Neoplasms 101Neoplasm Metastasis 70Breast Neoplasms 66Ovarian Neoplasms 42Urinary Bladder Neoplasms 37Lung Neoplasms 37Triple Negative Breast Neoplasms 34Colorectal Neoplasms 30Lymphoma, Large B-Cell, Diffuse 29Cholangiocarcinoma 28Biliary Tract Neoplasms 27Carcinoma, Transitional Cell 23Lymphoma, Non-Hodgkin 22Adenocarcinoma 22Recurrence 21Lymphoma 20Fallopian Tube Neoplasms 18Stomach Neoplasms 15Sarcoma 15Parkinson Disease 4, Autosomal Dominant Lewy Body 15Non-Muscle Invasive Bladder Neoplasms 13Carcinoma, Pancreatic Ductal 13Nasopharyngeal Carcinoma 12Gallbladder Neoplasms 12Bile Duct Neoplasms 11Melanoma 10Carcinoma 10Solid Tumors 9

Interventions

Gemcitabine 2130-nm albumin-bound paclitaxel 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Metastatic Pancreatic Ductal Adenocarcinoma × Gemcitabine × Clear all
NCT06646055 2026-03-09

AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer

Akeso

Phase 1/2 Active not recruiting
110 enrolled
Gastrointestinal

Metastatic Pancreatic Ductal Adenocarcinoma

NCT05630183 2025-11-13

A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer

Agenus Inc.

Phase 2 Active not recruiting
81 enrolled
Gastrointestinal

Metastatic Pancreatic Ductal Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡